Evidence map›Paper›PMID 25712822›Full record

ArticleBMJ open2015

Implications of private sector Hib vaccine coverage for the introduction of public sector Hib-containing pentavalent vaccine in India: evidence from retrospective time series data.

Abhishek Sharma, Warren A Kaplan, Maulik Chokshi, Habib Hasan Farooqui, Sanjay P Zodpey

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Abhishek SharmaDepartment of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA Center for Global Health and Development, Boston University School of Public Health, Boston, Massachusetts, USA.
Warren A KaplanDepartment of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA Center for Global Health and Development, Boston University School of Public Health, Boston, Massachusetts, USA.
Maulik ChokshiIndian Institute of Public Health, Public Health Foundation of India, New Delhi, India.
Habib Hasan FarooquiIndian Institute of Public Health, Public Health Foundation of India, New Delhi, India.
Sanjay P ZodpeyIndian Institute of Public Health, Public Health Foundation of India, New Delhi, India.
Institute of Public Health · INBoston University · USCenter for Global Health · USPublic Health Foundation of India · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveHaemophilus influenzae type b (Hib) vaccine has been available in India's private sector market since 1997. It was not until 14 December 2011 that the Government of India initiated the phased public sector introduction of a Hib (and DPT, diphtheria, pertussis, tetanus)-containing pentavalent vaccine. Our objective was to investigate the state-specific coverage and behaviour of Hib vaccine in India when it was available only in the private sector market but not in the public sector. This baseline information can act as a guide to determine how much coverage the public sector rollout of pentavalent vaccine (scheduled April 2015) will need to bear in order to achieve complete coverage.

setting16 of 29 states in India, 2009-2012.

designRetrospective descriptive secondary data analysis. DATA: (1) Annual sales of Hib vaccines, by volume, from private sector hospitals and retail pharmacies collected by IMS Health and (2) national household surveys. OUTCOME MEASURES: State-specific Hib vaccine coverage (%) and its associations with state-specific socioeconomic status.

resultsThe overall private sector Hib vaccine coverage among the 2009-2012 birth cohort was low (4%) and varied widely among the studied Indian states (minimum 0.3%; maximum 4.6%). We found that private sector Hib vaccine coverage depends on urban areas with good access to the private sector, parent's purchasing capacity and private paediatricians' prescribing practices. Per capita gross domestic product is a key explanatory variable. The annual Hib vaccine uptake and the 2009-2012 coverage levels were several times higher in the capital/metropolitan cities than the rest of the state, suggesting inequity in access to Hib vaccine delivered by the private sector.

conclusionsIf India has to achieve high and equitable Hib vaccine coverage levels, nationwide public sector introduction of the pentavalent vaccine is needed. However, the role of private sector in universal Hib vaccine coverage is undefined as yet but it should not be neglected as a useful complement to public sector services.

Indexed as

Bacterial CapsulesCost-Benefit AnalysisHaemophilus InfectionsHaemophilus influenzae type bHaemophilus VaccinesHumansImmunization ProgramsIndiaPrivate SectorPublic SectorRetrospective StudiesUniversal Health InsuranceVaccines, CombinedHaemophilus influenzae type b polysaccharide vaccineHaemophilus VaccinesVaccines, CombinedPrivate-sector Hib vaccine coverage

Identifiers

PMID25712822
PMCPMC4342586
OpenAlexW1967673515

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.